The Australian medical sector is abuzz with the emergence of retatrutide, a novel dual GIP and GLP-1 receptor showing significant results in clinical trials for treating obesity. This treatment suggests a https://highkeysocial.com/story7399953/retatrutide-australia-a-potential-solution-for-obesity-treatment